

Relationship between *Streptococcus mutans* expressing Cnm in the oral cavity and non-alcoholic steatohepatitis: a pilot study

Shuichi Tonomura ,¹ Shuhei Naka,² Keiko Tabata,² Tasuku Hara,³ Kojiro Mori,⁴ Saiyu Tanaka,⁴ Yoshio Sumida,⁵ Kazuyuki Kanemasa,⁴ Ryota Nomura,⁶ Michiyo Matsumoto-Nakano,² Masafumi Ihara,⁷ Nobuyuki Takahashi,⁸ Kazuhiko Nakano⁶

To cite: Tonomura S, Naka S, Tabata K, *et al.* Relationship between *Streptococcus mutans* expressing Cnm in the oral cavity and non-alcoholic steatohepatitis: a pilot study. *BMJ Open Gastro* 2019;**6**:e000329. doi:10.1136/bmjgast-2019-000329

Received 4 July 2019
Revised 3 September 2019
Accepted 14 September 2019

ABSTRACT

Background Non-alcoholic steatohepatitis (NASH) is a severe state of non-alcoholic fatty liver disease (NAFLD), which is pathologically characterised by steatosis, hepatocyte ballooning, and lobular inflammation. Host-microbial interaction has gained attention as one of the risk factors for NASH. Recently, *cnm*-gene positive *Streptococcus mutans* expressing cell surface collagen-binding protein, Cnm (*cnm*-positive *S. mutans*), was shown to aggravate NASH in model mice. Here, we assessed the detection rate of *cnm*-positive *S. mutans* in oral samples from patients with NASH among NAFLD.

Methods This single hospital cohort study included 41 patients with NAFLD. NASH was diagnosed histologically or by clinical score. The prevalence of *cnm*-positive *S. mutans*, oral hygiene and blood tests, including liver enzymes, adipocytokines and inflammatory and fibrosis markers, were assessed in biopsy-proven or clinically suspected NASH among NAFLD.

Results Prevalence of *cnm*-positive *S. mutans* was significantly higher in patients with NASH than patients without NASH (OR 3.8; 95% CI 1.02 to 15.5). The *cnm*-positive *S. mutans* was related to decreased numbers of naturally remaining teeth and increased type IV collagen 7S level (median (IQR) 10.0 (5.0–17.5) vs 20.0 (5.0–25.0), $p=0.06$; 5.1 (4.0–7.9) vs 4.4 (3.7–5.3), $p=0.13$, respectively).

Conclusions Prevalence of *cnm*-positive *S. mutans* in the oral cavity could be related to fibrosis of NASH among NAFLD.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and a major indicator of metabolic syndrome that is becoming increasingly prevalent worldwide.^{1 2} Non-alcoholic steatohepatitis (NASH), which is encapsulated within NAFLD, is an aggressive state that is pathologically defined by the presence of steatosis, hepatocyte ballooning and lobular inflammation,³ ultimately leading to cirrhosis,

Summary box

What is already known about this subject?

- ▶ Multiple parallel hits hypothesis is widely accepted for the pathogenesis of non-alcoholic steatohepatitis (NASH).
- ▶ The association of oral microbiota with NASH is poorly investigated.

What are the new findings?

- ▶ The prevalence of *cnm*-positive *Streptococcus mutans* in the oral cavity was associated with NASH.
- ▶ The prevalence of *cnm*-positive *S. mutans* in the oral cavity was associated with poor oral hygiene.

How might it impact on clinical practice in the foreseeable future?

- ▶ Future research is needed to explore the potential role of oral probiotics as a potential therapeutic target of NASH.

hepatocellular carcinoma and even a variety of cardiovascular diseases.^{4 5} As underlying mechanisms of NASH, the ‘multiple parallel hits’ hypothesis is widely accepted, which claims that fatty liver is the first stage leading to NASH, followed by parallel hits derived from various factors including microbiota, adipose tissue, and genetic factors.⁶ Focusing on the specific strain *Streptococcus mutans*, which is one of the major causative pathogens of dental caries, we suggested the role of this bacterium in development of systemic diseases including inflammatory bowel disease,⁷ immunoglobulin A nephropathy,⁸ and intracerebral haemorrhage.^{9 10} Moreover, we identified the contribution of *cnm* gene-positive *S. mutans* expressing the collagen-binding protein, Cnm, on the cell surface (*cnm*-positive *S. mutans*), to the aggravation of NASH in obesity model mice.^{11 12} However,



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Shuichi Tonomura;
tono0822shuichi@gmail.com



in humans, the relationship between NASH and oral hygiene, with a focus on *cnm*-positive *S. mutans* infection, remains unknown. Herein, we aimed to study the association between *cnm*-positive *S. mutans* and NASH.

SUBJECTS AND METHODS

Study subjects

In a single hospital-based, cross-sectional observational study, we collected outpatients who had been diagnosed with fatty liver disease using medical record within 5 years in Nara City Hospital from April 2017 to January 2018. Subjects who fulfilled eligibility criteria were collected and registered after obtaining written informed consent. All participants underwent physical examinations, blood tests, abdominal ultrasound, and questionnaires. Of all participants, subjects who had other causes of liver diseases (viral, autoimmune), consumed excessive amounts of alcohol (alcohol >30 g/day in men and 20 g/day in women),¹³ had no findings of fatty liver including hepatorenal echo contrast, bright liver, deep attenuation, or vascular blurring at the baseline assessment,¹⁴ withdrew informed consent, could not undergo oral sampling were excluded. This study was carried out in accordance with the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects (Public Notice of the Ministry of Health, Labor and Welfare No.475 of 2014). All subjects gave written informed consent in accordance with the Declaration of Helsinki.

NAFLD and NASH diagnosis

Diagnosis of NAFLD is based on the following criteria: (1) hepatic steatosis on imaging or histology, (2) no other cause of liver diseases (viral, autoimmune) and no significant alcohol consumption (alcohol >30 g/day in men and 20 g/day in women),¹³ and (3) no competing causes for hepatic steatosis. Liver biopsy remains the only reliable method to identify the severity of conditions that encapsulate NAFLD (ie, a condition that encompasses simple steatosis, NASH, and cirrhosis). For 16 subjects who underwent liver biopsy within 5 years, we referred to the pathological diagnosis of NASH following the NAFLD activity score.¹⁵ For subjects who did not undergo liver biopsy, conventional ultrasound was used to evaluate fatty liver clinical setting^{16 17} using Aplio 500 (Canon Medical Systems Co, Tochigi, Japan) and possible NASH was diagnosed using the NASH, ferritin, insulin, type IV collagen (NAFIC) score using ferritin, fasting insulin and type IV collagen 7S. In a previous cohort study, the sensitivity, specificity, positive predictive value, negative predictive value of NAFIC score ≥ 2 for NASH diagnosis were 60, 89, 85, and 64%, respectively.¹⁸

Risk factors and covariate assessments

Risk factors and covariates were evaluated using physical examination, blood tests, and self-reported questionnaires after receiving written informed consent. Body mass index (BMI) was defined as weight (in kg) divided by the square of height (in m). Obesity was defined as BMI ≥ 25 kg/m².¹⁹ Sitting blood pressure was measured

at 5 min intervals and the mean was used for analysis. Subjects were considered to have hypertension if they were taking antihypertensive medications, self-reported diagnosis of hypertension, or systolic blood pressure of ≥ 140 mmHg or diastolic pressure of ≥ 90 mmHg. Diabetes mellitus was defined as a fasting blood glucose level of ≥ 126 mg/dL or treatment with insulin or hypoglycaemic agents. For further assessments, insulin sensitivity and secretory ability were calculated using the fasting values of serum glucose and insulin according to homeostasis model assessment (HOMA) methods.²⁰ Dyslipidaemia was defined as fasting plasma triglyceride level ≥ 150 mg/dL, low-density lipoprotein cholesterol levels ≥ 140 mg/dL, or treatment with statins or fibrates. Liver enzymes including aspartate aminotransferase and alanine aminotransferase; liver fibrosis markers including platelet count, ferritin, and type IV collagen 7S; inflammatory markers including interleukin-6 and hypersensitive C-reactive protein and adipocytokines including adiponectin and tumour necrosis factor- α (TNF- α) were evaluated. Subjects were defined as never, past, or current smoker according to self-reported cigarette smoking habitation. Daily alcohol consumption was assessed by the questionnaires and subjects were defined as alcohol drinkers if they drank >30 g/day in men and 20 g/day in women.¹³ Oral hygiene was evaluated by the self-reported number of naturally remaining teeth^{21 22} and past dental treatment.

Oral sample collection

We asked subjects to visit the hospital at least 9 hour from their last meal. Oral samples were collected after light gargling with water. Dental plaque and saliva specimens were collected from subjects using Seed Swab (EIKEN Chemical Co, Tokyo, Japan) and 50 mL Eppendorf Conical Tube (Eppendorf AG, Hamburg, Germany), respectively. Oral samples were transported to Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and frozen at -20°C until analysis.

Bacterial strains and growth conditions

Oral samples were inoculated in Mitis-Salivarius (MS) agar plates (Difco Laboratories, Detroit, Michigan, USA) containing bacitracin (0.2 U/ml; Sigma-Aldrich Co, St Louis, Missouri, USA) and 15% sucrose (MSB plates), and then anaerobically incubated at 37°C for 48 hours. At least five colonies of *S. mutans* were isolated morphologically and cultured in brain heart infusion broth (Difco Laboratories) at 37°C for 24 hours.

DNA extraction and PCR method

S. mutans DNA was extracted using a previously described method.²³ Briefly, bacterial cells were collected and incubated with 62.5 μL of lysozyme chloride from chicken egg white (2.0 mg/mL; Sigma-Aldrich Co) and 0.25 μL of lysozyme hydrochloride from chicken egg white (10 mg/mL; Wako Pure Chemical Industries, Osaka, Japan) for 90 min at 37°C . Genomic DNA was then extracted using 600 μL of Cell Lysis solution (Qiagen, Düsseldorf, Germany)

and incubated at 80°C for 5 min, followed by addition of 3 µL of RNase A (10 mg/mL; Qiagen) to the mixture and incubation at 37°C for 30 min. In addition, 200 µL of protein precipitation solution (Qiagen) was added, vortexed vigorously for 20 min and then centrifuged at 10 000×g for 3 min. The supernatant was combined with 600 µL of isopropanol (Wako Pure Chemical Industries) and centrifuged. The precipitate was then resuspended with 70% ethanol (Wako Pure Chemical Industries), centrifuged at 10 000×g for 3 min, combined with 100 µL of DNA hydration solution (Qiagen) and stored as a DNA extract. Confirmation of *S. mutans* and presence of *cnm* gene was carried out by PCR using TaKaRa Ex Taq polymerase (TAKARA BIO, Shiga, Japan) with *S. mutans*-specific and *cnm*-specific primers,^{24 25} template DNA, and 1.5 mM of MgCl₂, according to the supplier's protocols. Amplification was performed using the following parameters. To detect *S. mutans*, 30 cycles of a denaturing step at 98°C for 10 s, and primer annealing and extension steps at 70°C for 1 min were performed. To detect the *cnm* gene, we performed initial denaturation at 95°C for 4 min, and then 30 cycles consisting of 95°C for 30 s, 60°C for 30 s and 72°C for 2 min, with a final extension at 72°C for 7 min. PCR products were subjected to electrophoresis in 1.5% or 0.7% agarose gel-Tris-acetate-EDTA buffer. The gel was stained with 0.5 µg of ethidium bromide per millilitre and photographed under ultraviolet illumination.

Statistical analyses

Continuous variables are presented as mean±SD, non-normal variables are reported as median and IQR,

and categorical variables are described as numbers and frequencies (%). To compare continuous, non-normal and categorical variables among groups, we used analysis of variance, Wilcoxon signed-rank test and Pearson's χ^2 test, respectively. To identify independent risk factors for NASH, logistic regression model analyses were performed based on previously identified factors and factors for which an association was suggested in univariate analysis ($p < 0.25$). ORs and 95% CIs were calculated for independent predictors of NASH. The statistical significance level was set at 0.05, additionally, the borderline significance level at 0.1 and the tendency at 0.2 for all analyses. All statistical analyses were conducted using JMP V.12.0 software (SAS Institute, Cary, North Carolina, USA).

RESULTS

Subject characteristics

Among the 117 subjects who fulfilled the eligibility criteria, 56 participants gave us written informed consent to participate in this study and underwent physical examinations, blood tests, oral sample collection, abdominal ultrasound, and questionnaires. Of these subjects, one subject withdrew after providing informed consent, one subject could not undergo oral sampling, and two subjects with alcoholic hepatitis and 11 subjects with normal findings were excluded. As a result, 41 subjects were registered for this study. Table 1 shows the subject characteristics. There were 19 male subjects (46.3%). The mean age was 67.0±10.3 years. BMI was 26.4±3.8 kg/m². Twenty-five subjects (61.0%) were classified as obese

Table 1 Subject's characteristics

Variables		Total (n=41)	NASH (n=19)	NAFLD (n=22)	P value
Age (years)	Mean (±SD)	67.0 (±10.3)	67.2 (±10.7)	66.9 (±10.2)	0.92
Male	n (%)	19 (46.3)	8 (42.1)	11 (50.0)	0.61
BMI (kg/m ²)	Mean (±SD)	26.4 (±3.8)	27.0 (±4.1)	25.9 (±3.6)	0.56
Obesity	n (%)	25 (61.0)	12 (63.2)	13 (59.1)	0.79
Smoker	n (%)	16 (39.0)	7 (36.8)	9 (40.9)	0.79
Current smoker	n (%)	5 (12.2)	2 (10.5)	3 (13.6)	0.76
Past smoker	n (%)	11 (26.8)	5 (26.3)	6 (27.3)	0.95
Alcohol	n (%)	14 (34.1)	7 (36.8)	7 (31.8)	0.74
Alcohol consumption (g/week)	median (IQR)	0.0 (0.0–5.9)	0.0 (0.0–0.0)	0.0 (0.0–8.5)	0.36
Hypertension	n (%)	31 (75.6)	24 (73.7)	17 (77.3)	0.79
Diabetes mellitus	n (%)	11 (26.8)	3 (15.8)	8 (36.4)	0.14
Hyperlipidaemia	n (%)	15 (36.6)	5 (26.3)	10 (45.5)	0.20
<i>Streptococcus mutans</i>	n (%)	34 (82.9)	16 (84.2)	18 (81.8)	0.84
<i>cnm</i> -positive <i>S. mutans</i>	n (%)	15 (36.6)	10 (62.5)	5 (27.8)	0.04
<i>cnm</i> -negative <i>S. mutans</i>	n (%)	19 (46.3)	6 (37.5)	13 (72.2)	
The number of teeth	mean (±SD)	14.4 (±8.3)	12.4 (±9.0)	16.3 (±7.4)	0.16
Edentulous	n (%)	3 (8.3)	3 (17.7)	0 (0.0)	0.06

Significant differences between groups were determined using the χ^2 test, Student's t-test or Wilcoxon signed-rank test. BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.




Figure 1 Relationship between the presence of *cnm*-positive *Streptococcus mutans* in the oral cavity and NASH. There was a significant difference in the prevalence of NASH among patients with NAFLD between subjects with *cnm*-positive *S. mutans* and those without or with *cnm*-negative *S. mutans*. * $P < 0.05$, as described by χ^2 test. NAFLD, non-alcoholic fatty liver diseases; NASH, non-alcoholic steatohepatitis.

(BMI ≥ 25.0 kg/m²). Five subjects (12.2%) were current smokers and 11 (26.8%) were past smokers. The median (IQR) of alcohol consumption was 0.0 (0.0–5.9) g/week. Hypertension, diabetes mellitus and dyslipidaemia were identified in 31 (71.6%), 11 (26.8%), and 15 (36.6%) subjects, respectively. In 16 subjects who underwent liver biopsy, 14 (87.5%) were diagnosed with NASH. Only five (20.0%) of the remaining 25 subjects who were clinically diagnosed with NAFLD fulfilled the criteria

for possible NASH. *S. mutans* and *cnm*-positive *S. mutans* were detected in 34 (82.9%) and 15 (36.6%) subjects, respectively.

cnm-positive *S. mutans* and NASH

There was no significant difference in prevalence of NASH among NAFLD between the *S. mutans*-positive group (n=34) and *S. mutans*-negative group (n=7) (3 (42.9%) vs 16 (47.1%); $p=0.84$) (figure 1). However, the prevalence of NASH among NAFLD was significantly higher in subjects with *cnm*-positive *S. mutans* compared with those without (10 (66.7%) vs 9 (34.6%); $p=0.05$) (OR 3.77, 95% CI 1.02 to 15.5) (figure 1B) or those with *cnm*-negative *S. mutans* (10 (66.7%) vs 6 (31.6%); $p=0.04$) (OR 4.33, 95% CI 1.02 to 18.38) (figure 1C). In subjects with *cnm*-positive *S. mutans*, type IV collagen 7S levels tended to be higher (median (IQR) 5.1 (4.0–7.9) vs 4.4 (3.7–5.3); $p=0.13$) and adiponectin levels tended to be lower (6.7 (4.1–10.8) vs 9.2 (7.1–13.9); $p=0.11$) compared with those without (table 2).

cnm-positive *S. mutans* and dental hygiene

Of 41 subjects, 36 answered the remaining number of teeth. Comparison of the *S. mutans*-positive group (n=30) with the *S. mutans*-negative group (n=6) revealed that there was no significant difference in the number of naturally remaining teeth (mean (SD): 14.8 (± 8.0) vs 12.5 (± 10.4); $p=0.54$) (figure 2A). However, in the *cnm*-positive *S. mutans* group (n=14), there was a borderline significant decreased number of naturally remaining teeth compared with those without (n=22) (11.4 (± 6.3) vs 16.4 (± 9.0); $p=0.08$) (figure 2B) and significantly decreased number of naturally remaining teeth compared with *cnm*-negative *S. mutans* group (n=16) (11.4 (± 6.3) vs 17.8 (± 8.4); $p=0.03$) (figure 2C). The number of naturally remaining teeth tended to be lower in subjects with NASH (n=17) compared with those with NAFLD (n=19) (12.4 (± 9.0) vs 16.3 (± 7.4); $p=0.16$) (figure 2D).

Table 2 Relationships between laboratory findings and *cnm*-positive *Streptococcus mutans*

Variable		<i>cnm</i> -positive <i>S. mutans</i>		P value
		(-)	(+)	
AST	(IU/mL)	27.5 (20.5–60.5)	34.0 (19.0–61.0)	0.91
ALT	(IU/mL)	31.5 (22.8–82.3)	33.0 (25.0–59.0)	0.97
Ferritin	(ng/mL)	168 (59–302)	158 (23–321)	0.68
Insulin	(μ IU/mL)	11.2 (7.1–18.2)	11.6 (5.4–18.2)	0.96
Type IV collagen 7S	(ng/mL)	4.4 (3.7–5.3)	5.1 (4.0–7.9)	0.13
Adiponectin	(μ g/mL)	9.2 (7.1–13.9)	6.7 (4.1–10.8)	0.10
TNF- α	(pg/mL)	1.04 (0.9–1.4)	1.05 (0.7–1.6)	0.90
hs-CRP	(μ g/mL)	728 (336–1845)	541 (186–1890)	0.36
IL-6	(pg/mL)	2.0 (1.7–3.3)	1.9 (1.6–3.3)	0.95

Data are expressed as median (IQR). Significant differences between groups were determined by the Wilcoxon signed-rank test. ALT, alanine aminotransferase; AST, aspartate aminotransferase; hs-CRP, hypersensitive C-reactive protein; IL-6, interleukin-6; TNF- α , tumour necrosis factor-alpha.




Figure 2 Number of naturally remaining teeth in subjects with *cnm*-positive *Streptococcus mutans* and those without. Subjects with *cnm*-positive *S. mutans* had fewer naturally remaining teeth compared with *cnm*-negative *S. mutans*. Data present the mean number of naturally remaining teeth \pm SE of the means. * $P < 0.05$, as described by Student's t-test. NAFLD, non-alcoholic fatty liver diseases; NASH, non-alcoholic steatohepatitis.

Logistic regression analysis with NASH as the independent variable

In univariate analysis, NASH was significantly associated with *cnm*-positive *S. mutans* and marginally related to the number of naturally remaining teeth and HOMA- β . In logistic regression analysis, only *cnm*-positive *S. mutans* was independently associated with NASH (OR (95% CI): 6.28 (1.29 to 40.8); $p = 0.02$) (table 3).

DISCUSSION

To our knowledge, we demonstrated, for the first time, the association between a specific strain of *S. mutans*, *cnm*-positive *S. mutans*, and NASH in human. The present study provided three essential findings to consider the aetiologies: (1) the possible pathway by which *cnm*-positive *S. mutans* acts on hepatic cells, (2) the association between the number

of naturally remaining teeth and presence of cariogenic bacteria, and (3) biomarkers reflecting the role of *cnm*-positive *S. mutans* in the development of NASH.

Potential pathway through which *cnm*-positive *S. mutans* acts on the liver

Our study surprisingly showed a significantly higher detection rate of *cnm*-positive *S. mutans* in subjects with NASH among NAFLD. However, it remains unknown whether this finding is consistent with previous animal studies. In animal models, intravenous administration of *cnm*-positive *S. mutans* was shown to accumulate in the liver and aggregated NASH,^{11 12} while we detected *cnm*-positive *S. mutans* in oral cavities, not in the blood. To explain this contradiction, it is necessary to introduce the unique host–pathogen interaction in the periodontal crevice and evaluate the bacterial properties of *S. mutans*. The gingival crevice, which lines the inside of the gingiva, is a particularly vulnerable site of the oral barrier. At the base of the sulcus where the mucosa connects to the tooth, the epithelium tapers down to 3–5 layers of thickness and allows constant passage of neutrophils from the tissue into the oral cavity²⁶ and microbes from the oral cavity into the tissue.²⁷ In fact, not only tissue trauma induced by procedures such as tooth extraction, periodontal probing, or scaling but also poor oral hygiene or toothbrushes can cause transient bacteraemia in human.²⁸ *S. mutans*, a facultative anaerobic Gram-positive coccus, can survive in the blood with higher oxygen partial pressure, while most periodontal pathogens are anaerobic. Furthermore, specific *S. mutans* strains can escape host immunity by inhibiting complement activation^{29 30} and can invade into human endothelial cells.³¹ Clinically, *S. mutans* is well known as one of the major pathogens for infective endocarditis³² and a recent study using real-time PCR detected *S. mutans* DNA in the oral cavities and atherosclerotic plaques, which implicate the direct interaction of *S. mutans* in systemic diseases through the bloodstream.³³ Based on these findings, we considered the direct effect of *cnm*-positive *S. mutans* on hepatic cells via transient bacteraemia for the progressive state of NASH. However, further research is necessary to confirm this mechanism and alternative aetiologies must be

Table 3 Univariate and multivariate analyses of risk factors associated with NASH

Variable	Univariate			Multivariate		
	OR	95% CI	P value	OR	95% CI	P value
Age (per 1 year)	0.90	0.09 to 9.09	0.10	1.04	0.96 to 1.14	0.38
Male (vs female)	1.38	0.40 to 4.84	0.61	2.89	0.59 to 18.7	0.20
<i>cnm</i> -positive+ <i>S. mutans</i> (+) versus (-)	3.77	1.02 to 15.5	0.046	6.28	1.29 to 40.8	0.02
Teeth (per one tooth)	1.35	0.92 to 2.11	0.28	1.35	0.81 to 2.40	0.25
HOMA- β	1.00	0.99 to 1.01	0.03	1.00	0.99 to 1.01	0.38

Significant factors associated with NASH were determined using univariate and logistic regression model analyses. HOMA, homeostasis model assessment.



considered, for example, chronic inflammation³⁴ or dysbiosis of gut microbiome driven by oral microbes.³⁵

Association between number of naturally remaining teeth and cariogenic bacteria

In this study, the number of naturally remaining teeth was significantly lower in subjects with *cnm*-positive *S. mutans* compared with those with *cnm*-negative *S. mutans*. The diagnostic validity of self-reported remaining number of teeth have been shown in multicohort studies.^{21 22} And many epidemiological studies have suggested an association between periodontal disease severity and decreased number of naturally remaining teeth in adults.^{36 37} Although there are few reports discussing the number of naturally remaining teeth and caries, especially focusing on *S. mutans*, high proportions of *S. mutans* were seen in supragingival plaques in patients with chronic periodontitis³⁸ incorporates, recently, there is an increasing number of root caries cases in the elderly population due to exposed root surfaces.³⁹ The correlation between *S. mutans* count in the oral cavity and naturally remaining teeth might be in line with these findings. Furthermore, Cnm has high affinity to the human extracellular matrix, especially type I and IV collagens. In the oral cavity, *cnm*-positive *S. mutans* should bind to dentin, which is contained under the enamel, and invade tooth roots, which are composed of type I collagen,⁴⁰ or dental pulp, which is composed of extracellular matrix.⁴¹

Biomarkers reflecting the role of *cnm*-positive *S. mutans* in the development of NASH

Although NASH model mice injected with *cnm*-positive *S. mutans* showed increased TNF- α levels,¹¹ there were no significant relationships between the oral pathogen and inflammatory biomarkers including hypersensitive C-reactive protein, interleukin-6 and TNF- α . Chronic inflammation associated with oral infectious diseases should be essential pathogenesis.⁴² As a limitation of this study, the duration between the diagnosis of NASH and oral or blood samplings varied between subjects. We considered that, in some subjects, the inflammation state of NASH might partially improve due to treatment or lifestyle change. However, our findings showed the interaction between *cnm*-positive *S. mutans* and aggregation of NASH. The tendency of higher type IV collagen 7S levels in subjects with *cnm*-positive *S. mutans*, which has higher affinity to type IV collagen, proposed an alternative bidirectional mechanism between oral caries and NASH. Type IV collagen is a major basement membrane protein of liver parasinusoidal cells.⁴³ After secretion of type IV collagen, the 7S domain in the NH₂-terminal polymerisation domain is inserted in tissues and released into the bloodstream by turnover in connective tissue. The increased type IV collagen 7S level correlated with the amount of fibrosis and increase in synthesis from fibroblasts following increasing fibrosis in the liver.^{44 45} Accumulating evidence demonstrates that fibrosis stage predicts the mortality and morbidity in NAFLD,⁴⁶ which

might support the clinical importance of the interaction between type IV collagen and *cnm*-positive *S. mutans*.

In summary, there are mainly two methodological limitations due to the pilot study. The main limitation is the small number of patients with biopsy-proven NASH. There are only 16 patients with histological confirmation for diagnosis of NASH. The other limitation is that we combined subjects with possible NASH due to clinical diagnostic score, which indicate our study incorporates potential errors (false positive and false negative). Even though our preliminary results are based on a small number of subjects, our pilot study does provide a possible association between *cnm*-positive *S. mutans* in the oral cavity and NASH. Larger scale evaluation and validation studies are statistically necessary to determine our findings and further assessment of specific biomarkers associated with specific bacteria. Moreover, experimental studies using animal models of dental caries using clinically isolated strains of the pathogen and NAFLD might be essential to elucidate the underlying mechanism of the oral-liver axis, *cnm*-positive *S. mutans* might be a possible modifiable factor of intervention for NASH.

Author affiliations

¹Department of Neurology, Nara City Hospital, Nara, Japan

²Department of Pediatric Dentistry, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan

³Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan

⁴Department of Gastroenterology and Hepatology, Nara City Hospital, Nara, Japan

⁵Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Aichi-gun, Japan

⁶Department of Pediatric Dentistry, Division of Oral Infection and Disease Control, Osaka University School of Dentistry Graduate School of Dentistry, Suita, Japan

⁷Department of Neurology, National Cerebral and Cardiovascular Center Hospital, Suita, Japan

⁸Department of Neurology, Nara City Hospital, Nara, Japan

Acknowledgements We thank Christina Croney, PhD, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.

Contributors Shuichi Tonomura, TH, KM, NT, Saiyu Tanaka, NT and YS participated in patient recruitment. Shuichi Tonomura and TH explained the study to patients, obtained written informed consent and collected oral samples. Shuichi Tonomura, SN, YS, KK, MI and NT designed the study. SN, KT and MM-N performed *Streptococcus mutans* detection and PCR. Shuichi Tonomura, SN and RN evaluated statistical analyses and drafted the manuscript. RN, MM-N, MI and KN interpreted the data and made substantial comments on the study. All authors approved the final draft submitted.

Funding This research was supported in part by a grant from the Smoking Research Foundation.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The protocol was approved by the ethical committee of Nara City Hospital, Nara, Japan (approval number: NCH 17–32).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

 Shuichi Tonomura <http://orcid.org/0000-0001-7092-2121>

REFERENCES

- 1 Williams CD, Stengel J, Asike MI, *et al.* Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011;140:124–31.
- 2 Younossi ZM, Koenig AB, Abdelatif D, *et al.* Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016;64:73–84.
- 3 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;64:1388–402.
- 4 Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med* 2010;363:1341–50.
- 5 Moreno-Del Castillo MC, Sanchez-Rodriguez A, Hernandez-Buen Abad JJ, *et al.* Importance of evaluating cardiovascular risk and hepatic fibrosis in patients with newly diagnosed nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2018.
- 6 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 2010;52:1836–46.
- 7 Kojima A, Nakano K, Wada K, *et al.* Infection of specific strains of *Streptococcus mutans*, oral bacteria, confers a risk of ulcerative colitis. *Sci Rep* 2012;2:332.
- 8 Misaki T, Naka S, Hatakeyama R, *et al.* Presence of *Streptococcus mutans* strains harbouring the *cnm* gene correlates with dental caries status and IgA nephropathy conditions. *Sci Rep* 2016;6:36455.
- 9 Nakano K, Hokamura K, Taniguchi N, *et al.* The collagen-binding protein of *Streptococcus mutans* is involved in haemorrhagic stroke. *Nat Commun* 2011;2.
- 10 Tonomura S, Ihara M, Kawano T, *et al.* Intracerebral hemorrhage and deep microbleeds associated with *cnm*-positive *Streptococcus mutans*; a hospital cohort study. *Sci Rep* 2016;6:20074.
- 11 Naka S, Hatakeyama R, Takashima Y, *et al.* Contributions of *Streptococcus mutans* Cnm and PA antigens to aggravation of non-alcoholic steatohepatitis in mice. *Sci Rep* 2016;6:36886.
- 12 Naka S, Wato K, Hatakeyama R, *et al.* Longitudinal comparison of *Streptococcus mutans*-induced aggravation of non-alcoholic steatohepatitis in mice. *J Oral Microbiol* 2018;10:1428005.
- 13 Sanyal AJ, Brunt EM, Kleiner DE, *et al.* Endpoints and clinical trial design for nonalcoholic steatohepatitis. *Hepatology* 2011;54:344–53.
- 14 Saadeh S, Younossi ZM, Remer EM, *et al.* The utility of radiological imaging in nonalcoholic fatty liver disease. *Gastroenterology* 2002;123:745–50.
- 15 Kleiner DE, Brunt EM, Van Natta M, *et al.* Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005;41:1313–21.
- 16 Tsai E, Lee T-P. Diagnosis and evaluation of nonalcoholic fatty liver Disease/Nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography. *Clin Liver Dis* 2018;22:73–92.
- 17 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. *Exp Diabetes Res* 2012;2012:1–12.
- 18 Sumida Y, Yoneda M, Hyogo H, *et al.* A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. *J Gastroenterol* 2011;46:257–68.
- 19 World Health Organization. *Obesity: preventing and managing the global epidemic. Report of a WHO consultation (WHO technical report series 894)*. World Health Organization, 2000: 1–253.
- 20 Matthews DR, Hosker JP, Rudenski AS, *et al.* Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–9.
- 21 Matsui D, Yamamoto T, Nishigaki M, *et al.* Validity of self-reported number of teeth and oral health variables. *BMC Oral Health* 2017;17.
- 22 Similä T, Nieminen P, Virtanen JI. Validity of self-reported number of teeth in middle-aged Finnish adults: the Northern Finland birth cohort study 1966. *BMC Oral Health* 2018;18:210.
- 23 Nakano K, Lapirattanakul J, Nomura R, *et al.* *Streptococcus mutans* clonal variation revealed by multilocus sequence typing. *J Clin Microbiol* 2007;45:2616–25.
- 24 Hoshino T, Kawaguchi M, Shimizu N, *et al.* PCR detection and identification of oral streptococci in saliva samples using *gtf* genes. *Diagn Microbiol Infect Dis* 2004;48:195–9.
- 25 Nomura R, Nakano K, Taniguchi N, *et al.* Molecular and clinical analyses of the gene encoding the collagen-binding adhesin of *Streptococcus mutans*. *J Med Microbiol* 2009;58:469–75.
- 26 Lamster IB. Evaluation of components of gingival crevicular fluid as diagnostic tests. *Ann Periodontol* 1997;2:123–37.
- 27 Parahitiyawa NB, Jin LJ, Leung WK, *et al.* Microbiology of odontogenic bacteremia: beyond endocarditis. *Clin Microbiol Rev* 2009;22:46–64.
- 28 Lockhart PB, Brennan MT, Sasser HC, *et al.* Bacteremia associated with toothbrushing and dental extraction. *Circulation* 2008;117:3118–25.
- 29 Kang M, Ko Y-P, Liang X, *et al.* Collagen-Binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway. *J Biol Chem* 2013;288:20520–31.
- 30 Araújo Alves L, Ganguly T, Mattos-Graner RO, *et al.* CovR and VicRKX Regulate Transcription of the Collagen Binding Protein Cnm of *Streptococcus mutans*. *J Bacteriol* 2018;200. doi:10.1128/JB.00141-18. [Epub ahead of print: 01 12 2018].
- 31 Abranches J, Miller JH, Martinez AR, *et al.* The collagen-binding protein Cnm is required for *Streptococcus mutans* adherence to and intracellular invasion of human coronary artery endothelial cells. *Infect Immun* 2011;79:2277–84.
- 32 Nakano K, Ooshima T. Serotype classification of *Streptococcus mutans* and its detection outside the oral cavity. *Future Microbiol* 2009;4:891–902.
- 33 Fernandes CP, Oliveira FAF, Silva PGdeB, *et al.* Molecular analysis of oral bacteria in dental biofilm and atherosclerotic plaques of patients with vascular disease. *Int J Cardiol* 2014;174:710–2.
- 34 Park SH, Kim BI, Yun JW, *et al.* Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. *J Gastroenterol Hepatol* 2004;19:694–8.
- 35 Bajaj JS, Betrapally NS, Hylemon PB, *et al.* Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. *Hepatology* 2015;62:1260–71.
- 36 Grytten J, Steele L, Holst D. Relationship between number of teeth and periodontal pockets. *Community Dent Oral Epidemiol* 1991;19:147–50.
- 37 Holmlund A, Holm G, Lind L. Severity of periodontal disease and number of remaining teeth are related to the prevalence of myocardial infarction and hypertension in a study based on 4,254 subjects. *J Periodontol* 2006;77:1173–8.
- 38 Dani S, Prabhu A, Chaitra KR, *et al.* Assessment of *Streptococcus mutans* in healthy versus gingivitis and chronic periodontitis: a clinico-microbiological study. *Contemp Clin Dent* 2016;7:529–34.
- 39 Preza D, Olsen I, Aas JA, *et al.* Bacterial profiles of root caries in elderly patients. *J Clin Microbiol* 2008;46:2015–21.
- 40 Nakano K, Nomura R, Taniguchi N, *et al.* Molecular characterization of *Streptococcus mutans* strains containing the *cnm* gene encoding a collagen-binding adhesin. *Arch Oral Biol* 2010;55:34–9.
- 41 Nomura R, Ogaya Y, Nakano K. Contribution of the collagen-binding proteins of *Streptococcus mutans* to bacterial colonization of inflamed dental pulp. *PLoS One* 2016;11:e0159613.
- 42 Åberg F, Helenius-Hietala J, Meurman J, *et al.* Association between dental infections and the clinical course of chronic liver disease. *Hepatol Res* 2014;44:349–53.
- 43 Mak KM, Chen LL, Lee T-F. Codistribution of collagen type IV and laminin in liver fibrosis of elderly cadavers: immunohistochemical marker of perisinusoidal basement membrane formation. *Anat Rec* 2013;296:953–64.
- 44 Murawaki Y, Ikuta Y, Koda M, *et al.* Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. *Hepatology* 1994;20:780–7.
- 45 Shimada M, Kawahara H, Ozaki K, *et al.* Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. *Am J Gastroenterol* 2007;102:1931–8.
- 46 Ekstedt M, Hagström H, Nasr P, *et al.* Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015;61:1547–54.